← Browse by Condition
Medical Condition
myelofibrosis mf
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, EARLY_Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for myelofibrosis mf sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — myelofibrosis mf Clinical Trials
How many clinical trials are currently recruiting for myelofibrosis mf?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for myelofibrosis mf, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myelofibrosis mf?
myelofibrosis mf research spans Phase 1 (3 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myelofibrosis mf clinical trial?
Eligibility criteria for myelofibrosis mf trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07362225
Recruiting
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Enrollment
5,000 pts
Location
United States
Sponsor
MPN Research Foundation
NCT07128381 Phase 1, Phase 2
Recruiting
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Enrollment
66 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06414681 EARLY_Phase 1
Recruiting
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Enrollment
20 pts
Location
United States
Sponsor
University of Kansas Medical C...
NCT06887803 Phase 1, Phase 2
Recruiting
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Enrollment
26 pts
Location
Italy, Spain, United...
Sponsor
iOnctura
NCT06541249 Phase 2
Recruiting
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Enrollment
54 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology